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ORIGINAL ARTICLE
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ABSTRACT
Background: Parity is known to have a protective effect as regards ovarian cancer, but its effect on
the different histological subtypes of ovarian cancer is not well known. The impact of parity on the
incidence of ovarian cancer subtypes was studied.
Material and methods: All Finnish women diagnosed 1994–2013 with ovarian cancer for the first
time were included. Altogether, 5412 cases of ovarian cancer were identified in the Finnish Cancer
Registry and stratified according to morphology into serous, mucinous, endometrioid, clear cell and
others. Five age-matched controls were randomly selected for each case from the Finnish National
Population Registry. Data on postmenopausal hormonal therapy were derived from the Registry of
Prescribed drugs and used as cofactors. Multivariate conditional logistic regression for matched case-
control data was used to examine the associations between parity parameters and ovarian cancer risk.
Results: Parous women had lower risk than nulliparous women in getting ovarian cancer of any type
under age of 55 years. The odds ratio (OR) for serous cancer was 0.65 (95% confidence interval
0.56–0.77), for mucinous cancer 0.66 (0.52–0.83), for endometrioid cancer 0.52 (0.40–0.68), for clear-cell
cancer 0.30 (0.19–0.46) and for other types 0.59 (0.43–0.80). In women aged 55 or older, the respective
ORs were 0.86 (0.75–0.99), 0.78 (0.57–1.07), 0.61 (0.47–0.79), 0.44 (0.29–0.66) and 0.74 (0.57–0.95),
adjusted for hormone therapy. Number of childbirths was associated with a trend toward reduction of
risk, especially in serous and clear-cell cancers. Higher age at first birth was associated with higher risk
of clear-cell cancer but otherwise age at first or last birth did not have an impact on the incidence of
cancer subtypes.
Conclusions: Childbirths decrease the risk of all histologic subtypes of epithelial ovarian cancer in
women in premenopausal and postmenopausal age.
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Ovarian cancer is the most lethal gynecologic cancer, with
more than 150 000 deaths worldwide annually [1]. Although
multiple carcinogenetic mechanisms have been hypothe-
sized, including incessant ovulation, hormonal stimulation
and chronic inflammation, the etiology of ovarian cancer is
still not well understood. Epithelial cancer accounts for about
90% of all malignant ovarian tumors [2]. It can be divided
into five major histological subtypes: serous (50%), mucinous
(5–14%), endometrioid (10–25%), clear cell (4–5%) and transi-
tional-cell (1–2%) tumors.
Recent evidence from histopathological and genetic stud-
ies suggests that the different histological subtypes of ovar-
ian cancer may have distinct, possibly extra-ovarian, origins.
For example, many high-grade serous tumors may arise from
precursor lesions within the Fallopian tubes, while endome-
trioid and clear-cell tumors may develop from endometri-
osis [3].
Previous studies on the role of reproductive risk factors in
the etiology of ovarian cancer have shown that increasing
parity decreases the risk of this disease, especially that of
epithelial cancer [4]. Pregnancy is associated with significant
changes in the metabolic and hormonal state. Circulating
levels of sex steroids during pregnancy are 10–100 times
higher than in nonpregnant women, which influences many
functions of reproductive and other organs. Cell differenti-
ation, proliferation and apoptosis may explain differences in
cancer incidence between parous and nulliparous women
[5,6]. Infertility has been associated with an increased risk of
ovarian cancer [6–8].
Many factors, including the use of oral contraceptives and
smoking show variation in their risk effects to different ovar-
ian cancer histotypes [3]. The association between the risk of
ovarian cancer and postmenopausal hormone therapy (HT) is
controversial [9–11] and varies by the histological type [12].
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There is a limited number of studies that have examined
the effects of childbirth on the incidence of different sub-
types of ovarian cancer and taken into account the impact of
HT. We therefore aimed to assess the risk of different epithe-
lial histological types of ovarian cancer in relation to parity in
both pre- and postmenopausal women, with adjustment for
HT in postmenopausal women.
Material and methods
Study population
Our study includes all Finnish women who were diagnosed
for the first time with ovarian cancer in 1994–2013.
Altogether, 5412 cases of ovarian cancer were identified in
the Finnish Cancer Registry (FCR; Table 1). Data recorded at
the FCR are collected from hospitals, pathology and hematol-
ogy laboratories, physicians and dentists, and death certifi-
cates [13]. We extracted information on ovarian cancer
histology from the FCR and classified cases into serous,
mucinous, endometrioid, clear cell and other cancers. The
category ‘other cancers’ included adenocarcinomas, carcino-
sarcomas, mesonephromas, carcinoid tumors, yolk sac
tumors, transitional cell carcinomas, mixed mesenchymal sar-
comas and non-specified tumors. The morphological codes
of cancer used by the FCR until 2007 were based on the
Manual of Tumor Nomenclature Coding (MOTNAC), after
which the codes were converted to and used as morphology
codes of ICD-O-3 [14] (Supplementary Table 1).
Five control women were randomly selected from the
National Population Registry (NPR) for each case of ovarian
cancer, matched by date of birth. Women who had emi-
grated or died before the index date, i.e. the date of ovarian
cancer diagnosis of the case, or women with ovarian cancer
were not eligible as controls. The NPR also provided informa-
tion on the dates of birth of biological children of the cases
and controls. We also linked the controls in the Care Register
for Health Care (HILMO) of the Finnish Institute for Health
and Welfare and excluded those who had undergone
oophorectomy, salpingectomy or sterilization before the
index date (n¼ 1074). Altogether, 26 022 control women
were included in the study. The characteristics of cases and
controls are shown in Table 1.
Exposure to postmenopausal HT
Data on the use of postmenopausal HT was obtained from
the nationwide Prescription Registry of the Social Insurance
Institution of Finland. This registry contains data on regular
purchases of HT since 1994. Medication for HT is available
only with a doctor’s prescription and is automatically regis-
tered. Purchase of estradiol (E) plus the levonorgestrel-releas-
ing intrauterine system (Eþ LNG-IUS) at the age of 45 or
older was taken into account as postmenopausal HT in our
study because such device is normally used for more than
five years. For other HT regimens, only purchases at the age
of 50 or older were regarded.
Postmenopausal HT use before the index date was cate-
gorized into E only, Eþ continuous progestin, Eþmonthly
progestin, Eþprogestin every 3months and Eþ LNG-IUS.
Progestin therapy combined with E was defined as continu-
ous when oral or transdermal E was combined daily with
progestin. In sequential progestin therapy, progestin was
combined with E for 10–14 days at 1- to 3-month intervals.
Eþ LNG-IUS therapy consisted of oral or transdermal estra-
diol added to low-dose levonorgestrel released by an intra-
uterine device.
Statistical methods
Multivariate conditional logistic regression for matched case-
control data was used to examine the associations between
Table 1. Characteristics of ovarian cancer cases and controls.
Cases Controlsa
N % N %
Total 5412 100.0 26 022 100.0
Histology
Serous 2862 52.88 13 713 52.70
Mucinous 767 14.17 3723 14.31
Endometrioid 755 13.95 3635 13.97
Clear-cell tumor 285 5.27 1369 5.26
Otherb 743 13.73 3582 13.77
Age
<55 years 2159 39.9 10 452 40.2
55þ years) 3253 60.1 15 570 59.8
Hormone therapy
Total 2118 39.1 9958 38.3
Estradiol-only therapy (50þ years) 556 10.3 2688 10.3
Estradiolþ continuous progestin therapy (50þ years) 627 11.6 2926 11.2
Estradiolþmonthly progestin therapy (50þ years) 734 13.6 3373 13.0
Progestin therapy in every 3months (50þ years) 126 2.3 606 2.3
Estradiolþ LNG-IUSc (45þ years) 75 1.4 365 1.4
N: number of cancer cases.
aFive control women without ovarian cancer were randomly selected from the National Population Registry for each case
of ovarian cancer.
bAdenocarcinomas, carcinosarcomas, mesonephromas, carcinoid tumors, yolk sac tumors, transitional cell carcinomas,
mixed mesenchymal sarcomas and non-specified tumors.
cLevonorgestrel-releasing intrauterine system (LNG-IUS).
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parity parameters and ovarian-cancer risk. Relative risks are
reported as odds ratios (ORs) with 95% confidence intervals
(95%CIs). The variables used in the models were parity (0, 1,
2, 3, 4, 5þ), age at first birth (<20, 20–24, 25–29, 30þ years),
and age at last birth (<30, 30–34, 35–39, 40þ years). In add-
ition to these variables, in analyses of risk of ovarian cancer
diagnosed in age 55 or higher, the durations of use of each
category of HT (<1 year, 1–5 years, 5þ years) were included
as covariates in the logistic regression models. Since the
average age of menopause in Finland is 51–52 years and
effects of HT on ovarian cancer risk are only seen at least
after 3 years of HT use [13], it is unlikely that we would see
any effect before the age of 55.
All calculations were carried out using R statis-
tical software.
Results
Parity and ovarian cancer risk
Serous cancer was the dominant type of epithelial ovarian
cancer among both pre- and postmenopausal women. It was
observed in 266 nulliparous and 741 parous women under
the age of 55 (<55), and in 291 nulliparous and 1564 parous
women in the age of 55 or higher (55þ). In ages <55, the
parous women had a reduced risk of serous ovarian cancer
(OR 0.65, 95%CI 0.56–0.77), as compared with nulliparous
women, and the risk decreased as the number of births
increased (Table 2). Similarly, parous women aged 55þ had a
reduced risk of serous ovarian cancer (OR 0.86, 95% CI
0.75–0.99), and the risk decreased with increasing parity
(Table 3). Age at first or last birth did not significantly affect
the risk of serous ovarian cancer at any age.
The risk of mucinous cancer in age <55 was reduced in
parous compared with nulliparous women (OR 0.66, 95% CI
0.52–0.83), but the risk did not markedly change with an
increasing number of births (Table 2). There was no signifi-
cant difference in risk of mucinous cancer in ages 55þ
between parous and nulliparous women (Table 3). Age at
first or last birth did not affect the OR at any age.
The OR for endometrioid ovarian cancer was significantly
decreased in parous women <55 years of age (OR 0.52, 95%
CI 0.40–0.68, Table 4), with a significant decrease observed
with increasing parity (p for linear trend 0.04). Similarly in
older women, there was a significant difference in risk
between parous and nulliparous women (OR 0.61, 95% CI
0.47–0.79), and the risk was significantly lower among
Table 2. Multivariate conditional logistic regression analysis for the parity, age
at first birth and age at last birth as predictors of serous and mucinous ovar-
ian cancer diagnosed among women aged <55 years.
Variable
Serous Mucinous
N OR 95%CI N OR 95%CI
Paritya
Nulliparous 266 1.00 Ref. 136 1.00 Ref.
Parous 741 0.65 0.56–0.77 310 0.66 0.52–0.83
Number of childrenb
1 221 1.00 Ref. 80 1.00 Ref.
2 330 0.78 0.64–0.96 146 1.00 0.72–1.39
3 140 0.64 0.48–0.85 59 0.87 0.57–1.34
4 32 0.42 0.27–0.66 13 0.70 0.34–1.42
5þ 18 0.64 0.35–1.16 12 0.91 0.41–2.00
Age at first birthb
<20 117 1.00 Ref. 55 1.00 Ref.
20–24 288 0.88 0.69–1.12 100 0.65 0.44–0.96
25–29 206 0.82 0.62–1.08 84 0.67 0.44–1.03
30þ 130 0.72 0.50–1.05 71 0.90 0.52–1.54
Age at last birthb
<30 410 1.00 Ref. 172 1.00 Ref.
30–34 212 1.13 0.89–1.43 91 1.10 0.77–1.56
35–39 105 1.25 0.91–1.71 40 0.86 0.52–1.41
40þ 14 0.64 0.36–1.24 7 0.70 0.28–1.72
N: number of cancer cases; OR: odds ratio; 95%CI: 95% confidence interval.
aThe model only included parity.
bThe model included number of children, and age at first and last birth.
Table 3. Multivariate conditional logistic regression analysis for the predictors




N OR 95%CI N OR 95%CI
Paritya
Nulliparous 291 1.00 Ref. 64 1.00 Ref.
Parous 1564 0.86 0.75–0.99 257 0.78 0.57–1.07
Number of childrenb
1 412 1.00 Ref. 76 1.00 Ref.
2 691 0.85 0.73–0.98 109 0.75 0.51–1.10
3 326 0.77 0.63–0.93 49 0.63 0.38–1.04
4 91 0.56 0.42–0.74 10 0.39 0.17–0.86
5þ 44 0.56 0.38–0.81 13 0.87 0.39–1.95
Age at first birthb
<20 221 1.00 Ref. 37 1.00 Ref.
20–24 754 1.08 0.91–1.28 114 0.90 0.58–1.38
25–29 426 1.02 0.83–1.25 70 1.04 0.63–1.72
30þ 163 0.88 0.66–1.18 36 1.18 0.58–2.41
Age at last birthb
<30 945 1.00 Ref. 142 1.00 Ref.
30–34 399 1.09 0.93–1.27 79 1.08 0.72–1.62
35–39 180 0.97 0.78–1.21 30 0.96 0.54–1.71
40þ 40 0.82 0.57–1.19 6 0.42 0.16–1.09
N: number of cancer cases; OR: odds ratio; 95%CI: 95% confidence interval.
aThe model included parity and hormonal therapy use.
bThe model included number of children, age at first and last birth and hor-
monal therapy use.
Table 4. Multivariate conditional logistic regression analysis for the predictors




N OR 95%CI N OR 95%CI
Paritya
Nulliparous 109 1.00 Ref. 51 1.00 Ref.
Parous 213 0.52 0.40–0.68 70 0.30 0.19–0.46
Number of childrenb
1 55 1.00 Ref. 33 1.00 Ref.
2 110 1.10 0.74–1.63 29 0.42 0.21–0.83
3 39 0.81 0.47–1.39 6 0.19 0.06–0.61
4 6 0.37 0.14–0.99 2 0.24 0.04–0.–51
5þ 3 0.38 0.10–1.47 0 — —
Age at first birthb
<20 24 1.00 Ref. 12 1.00 Ref.
20–24 110 2.02 1.22–3.33 32 0.79 0.33–1.90
25–29 47 1.22 0.69–2.18 12 0.38 0.12–1.20
30þ 32 1.13 0.52–2.42 14 0.53 0.13–2.20
Age at last birthb
<30 125 1.00 Ref. 46 1.00 Ref.
30–34 59 0.99 0.63–1.57 18 1.03 0.42–2.51
35–39 26 1.09 0.59–2.02 3 0.32 0.07–1.43
40þ 3 0.45 0.12–1.63 3 1.37 0.25–7.62
N: number of cancer cases; OR: odds ratio; 95%CI: 95% confidence interval.
aThe model only included parity.
bThe model included number of children, and age at first and last birth.
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biparous and triparous women as compared with uniparous
women (Table 5). Women diagnosed in age <55 who were
20–24 years at first birth had two-fold risk of endometrioid
cancer compared with those of less than 20 years at first
birth. Age at last birth did not affect the OR in either group.
The OR for clear-cell ovarian cancer was significantly
reduced in parous women compared with nulliparous
women (for age <55: OR 0.30, 95%CI 0.19–0.46, and for age
55þ: OR 0.44, 95%CI 0.29–0.66). No significant trend in ORs
was observed in relation to the number of births. An
increase in the OR of clear-cell cancer was observed with
increasing age at first birth in women aged 55þ (p for linear
trend 0.04; Tables 4 and 5).
The risk of other types of ovarian epithelial cancer was
lower in parous than in nulliparous women (for age <55: OR
0.59, 95% CI 0.43–0.80; for age 55þ: OR 0.74, 95% CI
0.57–0.95), and the risk seemed to decrease with increasing
number of births (Supplementary Tables 2 and 3).
Effect of HT on ovarian cancer in
postmenopausal women
The ORs for HT, derived from the multivariable model for
women at age 55þ, can be seen in Supplementary Tables
4–6. E only therapy increased the OR for serous ovarian can-
cer after five years of use (OR 1.32, 95% CI 1.08–1.62), while
continuous or sequential EPT did not. A significant reduction
in the risk of mucinous ovarian cancer was observed in
women who had used E only therapy, and the risk decreased
the longer the therapy lasted.
Discussion
The present results show that parous women had signifi-
cantly lower incidence of all histological types of epithelial
ovarian cancer than nulliparous women both in premeno-
pausal and postmenopausal ages.
It is well known that multiparity reduces the risk of ovar-
ian cancer, especially that of epithelial cancer [2–5,15,16].
Our results support these observations as the parity
decreased the risk of all epithelial cancer subtypes in women
aged <55. The risk decrease was about 70% in clear-cell can-
cer and 40%-50% in the other subtypes. In women aged
55þ, parous women also had reduced ORs, most strongly in
clear-cell cancer. Furthermore, compared to women with one
birth, increasing parity decreased the OR of especially serous
cancer in both age groups and clear-cell cancer in premeno-
pausal women. In the Million Women Study [3], parous
women had an estimated 26% lower risk of ovarian cancer
than nulliparous women and each additional birth was asso-
ciated with an overall 6% reduction in ovarian cancer risk.
Moreover, similarly to the present study in the study by
Wentzensen et al. [1] the largest reduction in risk was
observed in clear-cell tumors.
It has been speculated that the increased risk of clear-
cell and endometrioid ovarian cancer in nulliparous women
could be associated with infertility caused by endometri-
osis, as endometriosis has been linked to increased risk of
clear cell and endometrioid cancers [3,17–19]. Unfortunately
we did not have data on endometriosis of the cases and
controls and therefore we were not able to assess the role
of endometriosis in our results. Since severe endometriosis
is relatively rare, its possible confounding effect on ovarian
cancer risk is small. Other possible explanations for the
reduced risk in parous women are that pregnancy and lac-
tation act by interrupting the pro-inflammatory environ-
ment of incessant ovulation, by modifying the hormonal
environment or by clearing pre-malignant cells from the
ovary [3].
Earlier studies have shown conflicting results concerning
whether or not there is an association between age at first
or last birth and risk of ovarian cancer. In a study by
Whiteman et al. [20], women who were 30 years of age or
older at first or last birth had 30-50% lower risk of ovarian
cancer than those aged less than 20 at first birth or
25 years at last birth. In a study by Yang et al. [21] a trend
of increasing risk of ovarian cancer was observed with
increasing age at first birth, but no consistent pattern of
risk in relation to time since last birth and ovarian cancer
was found in another study [22]. Thus, there is no final
consensus on this issue yet. In the present study, age at
first and last birth did not affect the incidence of ovarian
epithelial cancer types at any age, except that of clear-cell
cancer in women aged 55þ, which increased along with
increasing age at first birth.
As prolonged use of HT may affect the risk of epithelial
ovarian cancer [9,13,23,24], we included HT in the models for
ovarian cancer in ages 55þ. We assumed that HT use started
at the age of menopause cannot have marked effect on
ovarian cancer risk before the age 55. We found that the OR
for serous ovarian cancer was moderately increased after 5
years use of E only while the risk of mucinous cancer was
decreased, and EPT did not alter the risk. These results are
Table 5. Multivariate conditional logistic regression analysis for the predictors




N OR 95%CI N OR 95%CI
Paritya
Nulliparous 101 1.00 Ref. 46 1.00 Ref.
Parous 332 0.61 0.47–0.79 118 0.44 0.29–0.66
Number of childrenb
1 95 1.00 Ref. 46 1.00 Ref.
2 134 0.66 0.48–0.93 46 0.57 0.34–0.98
3 68 0.62 0.41–0.94 17 0.58 0.27–1.24
4 24 0.72 0.40–1.30 6 0.44 0.15–1.31
5þ 11 0.51 0.23–1.11 3 0.79 0.16–3.80
Age at first birthb
<20 40 1.00 Ref. 12 1.00 Ref.
20–24 167 1.45 0.99–2.13 61 2.15 1.02–4.53
25–29 93 1.65 1.05–2.58 28 2.43 0.98–5.99
30þ 32 0.93 0.48–1.79 17 4.76 1.32–17.21
Age at last birthb
<30 201 1.00 Ref. 80 1.00 Ref.
30–34 86 0.99 0.70–1.40 24 0.50 0.24–1.15
35–39 33 0.95 0.57–1.56 10 0.29 0.11–0.79
40þ 12 1.23 0.60–2.53 4 0.47 0.12–1.82
N: number of cancer cases; OR: odds ratio; 95%CI: 95% confidence interval.
aThe model included parity and hormonal therapy use.
bThe model included number of children, age at first and last birth and hor-
monal therapy use.
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largely similar to those from earlier studies on HT and ovar-
ian cancer [2,12,25–27], indicating that the HT data used in
our study were accurate.
Our study is based on nation-wide registries that are com-
plete and reliable, and the large sample size ensured suffi-
cient power of the study. The NPR provides accurate
information on a very high proportion of childbirths of
women born after the mid 1930s, and the FCR is virtually
complete as regards cancer incidence since 1953 [14,15]. We
did not have information on the family history of ovarian
cancer. However, even if cancers in the family may affect
parity and hence be a potential confounder, its effect is small
because genetic ovarian cancer represents only about 5% of
total ovarian cancer cases in Finland [28]. We did not have
information on breastfeeding or use of hormonal contracep-
tives, which are known protective factors as regards ovarian
cancer [29,30].
In conclusion, we were able to demonstrate that parity
decreased the risk of main histological types of ovarian can-
cer even after adjustment for HT. The observations
strengthen the importance of awareness of the beneficial
health consequences associated with parity.
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